Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “FUNDING”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,081 records · Page 60

Shifting Sands: Modulating Interactions and Outputs of the CHIP‐Hsp70/HOP‐Hsp70 Protein Quality Control Complexes

The 70‐kilodalton heat shock protein (Hsp70) interacts with tetratricopeptide repeat (TPR) domains of CHIP (C‐terminus of Hsp70 Interacting Protein) and HOP (Hsp Organizing Protein) using a two‐carboxylate clamp binding mechanism. Differential affinity for the TPR domains of CHIP and HOP are achieved through interactions with the six residues preceding the carboxy‐terminal Asp 641 of Hsp70. In particular, phosphorylation of Hsp70 Thr 636 produces a dramatic swing in binding affinities that shift preferential formation of CHIP/Hsp70 complexes to preferential formation of HOP/Hsp70 complexes. Given that CHIP‐Hsp70 complexes promote ubiquitin‐mediated degradation of Hsp70‐chaperoned clients while HOP‐Hsp70 complexes promote refolding of Hsp70‐chaperoned clients, phosphorylation of Hsp70 Thr 636 acts as a switch that directs the output and function of cellular protein quality control. Herein, through biophysical assays and new structures of CHIP‐Hsp70 and Hop‐Hsp70 we identify the molecular mechanism that enables phosphorylation‐driven switching that directs interactions within the CHIP‐Hsp70/HOP‐Hsp70 protein quality control complexes. We also present a structure‐guided mutation of Hsp70 that bypasses Thr 636 phosphorylation‐driven switching by recovering affinity of CHIP for phosphorylated Hsp70, thereby redirecting Hsp70 to preferentially bind to CHIP. This structure‐guided mutation corrects a binding defect present in wild type CHIP and provides a system for studying the effect of shifting output of the CHIP‐Hsp70/HOP‐Hsp70 protein quality control complexes toward chaperoned ubiquitination via the CHIP‐Hsp70 complex. Support or Funding Information The authors acknowledge financial support from the US National Science Foundation (Award No. MCB 1552113 to RCP), the American Heart Association (Award No. 16SDG26960000 to RCP), the Burroughs Wellcome Fund (Award No. 1014031 to RCP), and institutional support from Miami University through the Robert H. and Nancy J. Blayney Professorship (to RCP). The Advanced Light Source is supported by the US Department of Energy under contract number DE‐AC03‐76SF00098 at Lawrence Berkeley National Laboratory.

Page, Richard C.↗

Interactions and Dynamics Within CHIP/Hsp70 Complexes

Interactions between the E3 ubiquitin ligase CHIP (C‐terminus of Hsp70 interacting protein) and the chaperone Hsp70 represent the physical intersection of two competing protein quality control efforts: refolding, and degradation. Interaction with CHIP allows for the formation of a productive encounter complex that facilitates ubiquitination of Hsp70‐bound substrates, thereby targeting those proteins for proteasomal degradation. Central to the CHIP/Hsp70 interaction are changes in structure and dynamics that occur upon binding. Although recruitment of Hsp70 to CHIP via interaction with the CHIP tetratricopeptide repeat (TPR) domain is well established, alterations in structure and dynamics of CHIP and Hsp70 upon binding are not well understood. Using NMR we describe residue‐level changes in dynamics to the CHIP‐TPR domain that occur upon binding Hsp70. We also utilize small angle X‐ray scattering (SAXS) and electron paramagnetic resonance (EPR) to identify motions with the CHIP/Hsp70 complex. Independent SAXS and EPR experiments both point to a mobile Hsp70 substrate binding domain that is only partially constrained through interactions with the CHIP‐TPR. Building upon static models of the full‐length CHIP/Hsp70 complex, afforded by our recent crystal structure of the CHIP‐TPR/Hsp70‐lid‐tail complex, we have assembled a dynamic model of the CHIP‐Hsp70 complex. This dynamic model sheds light on the function of the CHIP/Hsp70 chaperoned ubiquitination complex and how CHIP harnesses dynamics of Hsp70 to overcome significant distance separations identified in earlier static models of the CHIP/Hsp70 complex. Support or Funding Information The authors acknowledge financial support from the US National Science Foundation (Award No. MCB 1552113 to RCP), the American Heart Association (Award No. 16SDG26960000 to RCP), the Burroughs Wellcome Fund (Award No. 1014031 to RCP), and institutional support from Miami University through the Robert H. and Nancy J. Blayney Professorship (to RCP). The Advanced Light Source is supported by the US Department of Energy under contract number DE‐AC03‐76SF00098 at Lawrence Berkeley National Laboratory.

Mannion, Matthew M.↗

PIP4Kγ as a potential target for Huntington's disease

Phosphoinositide lipids provide spatial and temporal regulation of cell signaling and membrane traffic. The PI5P‐4‐kinase family is one of the less studied phosphoinositide lipid kinases. These enzymes catalyze the conversion of phosphatidylinositol 5‐phosphate to phosphatidylinositol 4,5‐bis phosphate. A recent study by Vicinanza et al., a suggested that depletion of the PI5P‐4‐kinase, PIP4Kγ promotes a non‐canonical autophagy pathway. Moreover, this depletion reduced the presence of huntingtin‐exon1‐polyglutamine aggregates. Expression of exon1 of huntingtin with an extended polyglutamine tract is a model for huntingtin protein aggregates. To further test the hypothesis that PIP4Kγ is a potential target to reduce huntingtin aggregates, we tested the depletion of PIP4Kγ in cell culture models that express full length mutant huntingtin (mHtt). We determined that depletion of PIP4Kγ, but not PIP4Kα or PIP4Kβ, lowers the levels of mHtt in patient fibroblasts and in immortalized Hdh Q111 mouse striatal neurons. We show that PIP4Kγ‐dependent depletion of mHtt requires lysosomal function because the depletion is blocked by the lysosomal inhibitor, bafilomycin A1. Moreover, we show that depletion of PIP4Kγ increases autophagic flux, as measured by an increase in LC3‐II levels by western blot analysis and an increase in LC3‐II puncta by microscopy. Our studies suggest that PIP4kγ should be further pursued as a target for Huntington's disease. Support or Funding Information This work was supported by AHA postdoctoral fellowship 14POST20480137 (Sai Srinivas Panapakkam Giridharan), NIH grants R01GM050403 and NS064015 (Lois S Weisman) and by HSS funding 1R03MH084839 (Juan Marugan)

Giridharan, Sai Srinivas Panapakkam↗

Applications of the second virial coefficient: protein crystallization and solubility

This article highlights some of the ground-based studies emanating from NASA’s Microgravity Protein Crystal Growth (PCG) program, and includes a more detailed discussion of the history and the progress made in one of the NASA-funded PCG investigations involving the use of measured second virial coefficients (B values) as a diagnostic indicator of solution conditions conducive to protein crystallization. This article begins by highlighting some of the ground-based studies emanating from NASA’s Microgravity Protein Crystal Growth (PCG) program. This is followed by a more detailed discussion of the history of and the progress made in one of the NASA-funded PCG investigations involving the use of measured second virial coefficients (B values) as a diagnostic indicator of solution conditions conducive to protein crystallization. A second application of measured B values involves the determination of solution conditions that improve or maximize the solubility of aqueous and membrane proteins. These two important applications have led to several technological improvements that simplify the experimental expertise required, enable the measurement of membrane proteins and improve the diagnostic capability and measurement throughput.

75 CONDENSED MATTER PHYSICS, SUPERCONDUCTIVITY AND↗

IEEE PES Resource Center

About 11 years ago, the U.S. Department of Energy (DOE) funded the Pacific Northwest National Laboratory (PNNL) to conduct one of the first-ever field demonstrations of what later became called a transactive system. Transactive systems have since become important tools in the DOE’s research efforts to modernize the U.S. electric power grid and conserve energy in U.S. buildings. The DOE currently funds fundamental and applied research to advance transactive system technologies, including their simulation, standardization, theoretical principles, valuation, demonstration, and automation. This article will discuss both the historical and recent DOE research and development activities in this topic area, including especially a recent PNNL report concerning the valuation of transactive systems.

transacitve energy↗

High-Performance Molecular Dynamics Simulation for Biological and Materials Sciences: Challenges of Performance Portability, Dallas, TX, November 2018.

Highly-optimized parallel molecular dynamics programs have allowed researchers to achieve ground-breaking results in biological and materials sciences. This type of performance has come at the expense of portability: a significant effort is required for performance optimization on each new architecture. Using a metric that emphasizes speedup, we assess key accelerating programming components of four different best-performing molecular dynamics programs - GROMACS, NAMD, LAMMPS and CP2K-- each having a particular scope of application, for contribution to performance and for portability. We use builds with and without these components, tested on HPC systems. We also analyze the code-bases to determine compliance with portability recommendations. We find that for all four programs, the contributions of the non-portable components to speed are essential to the programs' performances; without them we see a reduction in time-to-solution of a magnitude that is insufferable to domain scientists. This characterizes the performance efficiency that must be approached for good performance portability on a programmatic level, suggesting solutions to this difficult problem, which should come from developers, industry and funding institutions, and possibly new research in programming languages.

Computer Science↗

Applying Utility's Advanced Grid Technologies to Improve Resiliency of a Critical Load

The US DOE Office of Electricity's Energy Storage Program's joint R&D work with the Cordova Electric Cooperative (CEC) has deployed several advanced grid technologies that are providing benefits today to Cordova Alaska's electricity users. Advanced grid technologies deployed through DoE co-funded R&D include a 1MW Battery Energy Storage System (BESS), and enhanced monitoring including Phasor Measurement Units (PMU's) to help better understand the operational impacts of the added BESS. This paper will highlight key accomplishments to-date in deploying and using advanced grid technologies, and then outline the next phase of work that will use these technologies to implement an operating scheme to reconfigure the utility's distribution system and utility resources including BESS to provide emergency back-up power to a critical load: the Cordova Community Medical Center (CCMC). This paper will include additional insights on the use of utility resources to support critical loads via case study examples by the National Rural Electric Cooperative Assoc. (NRECA).

BESS↗

SU-C-18C-06: Radiation Dose Reduction in Body Interventional Radiology: Clinical Results Utilizing a New Imaging Acquisition and Processing Platform

Purpose: To quantify the patient radiation dose reduction achieved during transarterial chemoembolization (TACE) procedures performed in a body interventional radiology suite equipped with the Philips Allura Clarity imaging acquisition and processing platform, compared to TACE procedures performed in the same suite equipped with the Philips Allura Xper platform. Methods: Total fluoroscopy time, cumulative dose area product, and cumulative air kerma were recorded for the first 25 TACE procedures performed to treat hepatocellular carcinoma (HCC) in a Philips body interventional radiology suite equipped with Philips Allura Clarity. The same data were collected for the prior 85 TACE procedures performed to treat HCC in the same suite equipped with Philips Allura Xper. Mean values from these cohorts were compared using two-tailed t tests. Results: Following installation of the Philips Allura Clarity platform, a 42.8% reduction in mean cumulative dose area product (3033.2 versus 1733.6 mGycm∧2, p < 0.0001) and a 31.2% reduction in mean cumulative air kerma (1445.4 versus 994.2 mGy, p < 0.001) was achieved compared to similar procedures performed in the same suite equipped with the Philips Allura Xper platform. Mean total fluoroscopy time was not significantly different between the two cohorts (1679.3 versus 1791.3 seconds, p = 0.41). Conclusion: This study demonstrates a significant patient radiation dose reduction during TACE procedures performed to treat HCC after a body interventional radiology suite was converted to the Philips Allura Clarity platform from the Philips Allura Xper platform. Future work will focus on evaluation of patient dose reduction in a larger cohort of patients across a broader range of procedures and in specific populations, including obese patients and pediatric patients, and comparison of image quality between the two platforms. Funding for this study was provided by Philips Healthcare, with 5% salary support provided to authors K. Pallav Kolli and Robert G. Gould for time devoted to the study. Data acquisition and analysis was performed by the authors independent of the funding source.

60 APPLIED LIFE SCIENCES↗

SU-D-BRE-01: A Realistic Breathing Phantom of the Thorax for Testing New Motion Mitigation Techniques with Scanning Proton Therapy

Purpose: A prototype breathing phantom (named LuCa) has been developed which simulates the anatomy and motion of a patient thorax.In this work, we describe the results of the first commissioning tests with LuCa. Methods: The phantom provides a close representation of the human thorax. The lungs,contained within a tissue-equivalent ribcage and skin,are made from a polymer foam,which is inflated and deflated using a custommade ventilator. A tumor is simulated using a wooden ball with cutplanes for placing GafChromic films. The ventilator,controlled with Labview software,simulates a full range of breathing motion types.Commissioning tests were performed to assess its performance using imaging (CT and radiographic) and film dosimetry as follows:i)maximum Tumor excursion at acceptable pressure ranges, ii)tumor Motion repeatability between breathing periods,iii)reproducibility between measurement days,iv)tumor-to-surface motion correlation and v)reproducibility of film positioning in phantom. Results: The phantom can generate repeatable motion patterns with sin{sup 4},sin,breath-hold (tumor amplitude repeatability <0.5mm over 10min),aswell as patient-specific motion types. Maximum excursions of the tumor are 20mm and 14mm for the large and small tumor inserts respectively. Amplitude reproducibility (Coefficient of Variation) averaged at 16% for the workable pressure range over 2 months. Good correlation between tumor and surface motion was found with R{sup 2}=0.92. Reproducibility of film positioning within the thorax was within 0.9mm, and maximum 3° error from the coronal plane. Film measurements revealed that the film repositioning error yields relative errors in the mean dose over the planned target volume (PTV) of up to 2.5% and 4.5% for films at the center and on the edge of the PTV respectively. Conclusion: Commissioning tests have shown that the LuCa phantom can produce tumor motion with excellent repeatability. However,a poorer performance in reproducibility of tumor amplitude for a given peak pressure week-to-week. Film set-up reproducibility is adequate for detection of dosimetric errors resulting from motion of >3%. This work is funded by Swiss National Fund Grants 320030-127569 and 320030-1493942-1.

60 APPLIED LIFE SCIENCES↗

SU-E-I-59: Image Quality and Dose Measurement for Partial Cone-Beam CT

Purpose: To characterize performance of cone beam CT (CBCT) used in dentistry investigating quantitatively the image quality and radiation dose during dental CBCT over different settings for partial rotation of the x-ray tube. Methods: Image quality and dose measurements were done on a variable field of view (FOV) dental CBCT (Carestream 9300). X-ray parameters for clinical settings were adjustable for 2–10 mA, 60–90 kVp, and two optional voxel size values, but time was fixed for each FOV. Image quality was assessed by scanning cylindrical poly-methyl methacrylate (PMMA) image quality phantom (SEDENTEXCT IQ), and then the images were analyzed using ImageJ to calculate image quality parameters such as noise, uniformity, and contrast to noise ratio (CNR). A protocol proposed by SEDENTEXCT, dose index 1 (DI1), was applied to dose measurements obtained using a thimble ionization chamber and cylindrical PMMA dose index phantom (SEDENTEXCT DI). Dose distributions were obtained using Gafchromic film. The phantoms were positioned in the FOV to imitate a clinical positioning. Results: The image noise was 6–12.5% which, when normalized to the difference of mean voxel value of PMMA and air, was comparable between different FOVs. Uniformity was 93.5ß 99.7% across the images. CNR was 1.7–4.2 and 6.3–14.3 for LDPE and Aluminum, respectively. Dose distributions were symmetric about the rotation angle's bisector. For large and medium FOVs at 4 mA and 80–90 kVp, DI1 values were in the range of 1.26–3.23 mGy. DI1 values were between 1.01–1.93 mGy for small FOV (5×5 cm{sup 2}) at 4–5 mA and 75–84 kVp. Conclusion: Noise decreased by increasing kVp, and the CNR increased for each FOV. When FOV size increased, image noise increased and CNR decreased. DI1 values were increased by increasing tube current (mA), tube voltage (kVp), and/or FOV. Funding for this project from NSERC Discovery grant, UBC Faculty of Dentistry Research Equipment Grant and UBC Faculty of Dentistry S. Wah Leung Endowment Fund.

46 INSTRUMENTATION RELATED TO NUCLEAR SCIENCE AND ↗

SU-E-J-170: Beyond Single-Cycle 4DCT: Maximum a Posteriori (MAP) Reconstruction-Based Binning-Free Multicycle 4DCT for Lung Radiotherapy

Purpose: Thoracic motion changes from cycle-to-cycle and day-to-day. Conventional 4DCT does not capture these cycle to cycle variations. We present initial results of a novel 4DCT reconstruction technique based on maximum a posteriori (MAP) reconstruction. The technique uses the same acquisition process (and therefore dose) as a conventional 4DCT in order to create a high spatiotemporal resolution cine CT that captures several breathing cycles. Methods: Raw 4DCT data were acquired from a lung cancer patient. The continuous 4DCT was reconstructed using MAP algorithm which uses the raw, time-stamped CT data to reconstruct images while simultaneously estimating deformation in the subject's anatomy. This framework incorporates physical effects such as hysteresis and is robust to detector noise and irregular breathing patterns. The 4D image is described in terms of a 3D reference image defined at one end of the hysteresis loop, and two deformation vector fields (DVFs) corresponding to inhale motion and exhale motion respectively. The MAP method uses all of the CT projection data and maximizes the log posterior in order to iteratively estimate a timevariant deformation vector field that describes the entire moving and deforming volume. Results: The MAP 4DCT yielded CT-quality images for multiple cycles corresponding to the entire duration of CT acquisition, unlike the conventional 4DCT, which only yielded a single cycle. Variations such as amplitude and frequency changes and baseline shifts were clearly captured by the MAP 4DC Conclusion: We have developed a novel, binning-free, parameterized 4DCT reconstruction technique that can capture cycle-to-cycle variations of respiratory motion. This technique provides an invaluable tool for respiratory motion management research. This work was supported by funding from the National Institutes of Health and VisionRT Ltd. Amit Sawant receives research funding from Varian Medical Systems, Vision RT and Elekta.

60 APPLIED LIFE SCIENCES↗

SU-E-J-235: Varian Portal Dosimetry Accuracy at Detecting Simulated Delivery Errors

Purpose: To use receiver operating characteristic (ROC) analysis to quantify the Varian Portal Dosimetry (VPD) application's ability to detect delivery errors in IMRT fields. Methods: EPID and VPD were calibrated/commissioned using vendor-recommended procedures. Five clinical plans comprising 56 modulated fields were analyzed using VPD. Treatment sites were: pelvis, prostate, brain, orbit, and base of tongue. Delivery was on a Varian Trilogy linear accelerator at 6MV using a Millenium120 multi-leaf collimator. Image pairs (VPD-predicted and measured) were exported in dicom format. Each detection test imported an image pair into Matlab, optionally inserted a simulated error (rectangular region with intensity raised or lowered) into the measured image, performed 3%/3mm gamma analysis, and saved the gamma distribution. For a given error, 56 negative tests (without error) were performed, one per 56 image pairs. Also, 560 positive tests (with error) with randomly selected image pairs and randomly selected in-field error location. Images were classified as errored (or error-free) if percent pixels with γ<κ was < (or ≥) τ. (Conventionally, κ=1 and τ=90%.) A ROC curve was generated from the 616 tests by varying τ. For a range of κ and τ, true/false positive/negative rates were calculated. This procedure was repeated for inserted errors of different sizes. VPD was considered to reliably detect an error if images were correctly classified as errored or error-free at least 95% of the time, for some κ+τ combination. Results: 20mm{sup 2} errors with intensity altered by ≥20% could be reliably detected, as could 10mm{sup 2} errors with intensity was altered by ≥50%. Errors with smaller size or intensity change could not be reliably detected. Conclusion: Varian Portal Dosimetry using 3%/3mm gamma analysis is capable of reliably detecting only those fluence errors that exceed the stated sizes. Images containing smaller errors can pass mathematical analysis, though may be detected by visual inspection. This work was not funded by Varian Oncology Systems. Some authors have other work partly funded by Varian Oncology Systems.

60 APPLIED LIFE SCIENCES↗

SU-E-T-364: 6X FFF and 10X FFF Portal Dosimetry Output Factor Verification: Application for SRS/SBRT

Purpose: To enhance portal dosimetry of high dose rate SRS/SBRT plan verifications with extensive imager measurement of output factors (OF). Methods: Electronic portal image dosimetry (EPID), implemented on the Varian Edge allows for acquisition of its two energies: 6X FFF and 10 FFF (1400 and 2400 MU/min, respectively) at source to imager distance (SID) =100cm without imager saturation. Square and rectangular aSi OF following EPID calibration were obtained. Data taken was similar to that obtained during beam commissioning (of almost all field sizes from 1×1 to 15×15 and 20×20 cm{sup 2}, [Trilogy] and [Edge], respectively) to construct a table using the OF tool for use in the Portal Dosimetry Prediction Algorithm (PDIP v11). The Trilogy 6x SRS 1000 MU/min EPID data were taken at 140 SID. The large number of OF were obtained for comparison to that obtained with diode detectors and ion chambers (cc13 for >3×3 field size). As Edge PDIP verification is currently ongoing, EPID measurements of three SRS/SBRT plans for the Trilogy were taken and compared to results obtained prior to these measurements. Results: The relative difference output factors of field sizes 2×2 and higher compared to commissioning data were (mean+/-SD, [range]): Edge 6X (−1.9+/−2.9%, [−5.9%,3.1%]), Edge 10X (−0.7+/−1.2%, [− 3.3%,0.8%] and Trilogy (0.03+/−0.5%, [−1.4%,1.1%]) with EPID over predicting. The results for the 140 SID showed excellent agreement throughout except at the 1×1 to 1×15 and 15×1 field sizes where differences were: −10.6%, −6.0% and −5.8%. The differences were also most pronounced for the 1×1 at 100 SID. They were −7.4% and −11.5% for 6X and 10X, respectively. The Gamma (3%, 1mm) for three clinical plans improved by 8.7+/−1.8%. Conclusion: Results indicate that imager output factor measurements at any SID of high dose rate SRS/SBRT are quite reliable for portal dosimetry plan verification except for the smallest fields. This work was not funded by Varian Oncology Systems. Some authors have other work partly funded by Varian Oncology Systems.

46 INSTRUMENTATION RELATED TO NUCLEAR SCIENCE AND ↗

SU-E-T-512: Electromagnetic Simulations of the Dielectric Wall Accelerator

Purpose: To characterize and parametrically study the key components of a dielectric wall accelerator through electromagnetic modeling and particle tracking. Methods: Electromagnetic and particle tracking simulations were performed using a commercial code (CST Microwave Studio, CST Inc.) utilizing the finite integration technique. A dielectric wall accelerator consists of a series of stacked transmission lines sequentially fired in synchrony with an ion pulse. Numerous properties of the stacked transmission lines, including geometric, material, and electronic properties, were analyzed and varied in order to assess their impact on the transverse and axial electric fields. Additionally, stacks of transmission lines were simulated in order to quantify the parasitic effect observed in closely packed lines. Particle tracking simulations using the particle-in-cell method were performed on the various stacks to determine the impact of the above properties on the resultant phase space of the ions. Results: Examination of the simulation results show that novel geometries can shape the accelerating pulse in order to reduce the energy spread and increase the average energy of accelerated ions. Parasitic effects were quantified for various geometries and found to vary with distance from the end of the transmission line and along the beam axis. An optimal arrival time of an ion pulse relative to the triggering of the transmission lines for a given geometry was determined through parametric study. Benchmark simulations of single transmission lines agree well with published experimental results. Conclusion: This work characterized the behavior of the transmission lines used in a dielectric wall accelerator and used this information to improve them in novel ways. Utilizing novel geometries, we were able to improve the accelerating gradient and phase space of the accelerated particle bunch. Through simulation, we were able to discover and optimize design issues with the device at low cost. Funding: Morgridge Institute for Research, Madison WI; Conflict of Interest: Dr. Mackie is an investor and board member at CPAC, a company developing compact accelerator designs similar to those discussed in this work, but designs discussed are not directed by CPAC. Funding: Morgridge Institute for Research, Madison WI; Conflict of Interest: Dr. Mackie is an investor and board member at CPAC, a company developing compact accelerator designs similar to those discussed in this work, but designs discussed are not directed by CPAC.

43 PARTICLE ACCELERATORS↗

SU-E-T-551: PTV Is the Worst-Case of CTV in Photon Therapy

Purpose: To examine the supposition of the static dose cloud and adequacy of the planning target volume (PTV) dose distribution as the worst-case representation of clinical target volume (CTV) dose distribution for photon therapy in head and neck (H and N) plans. Methods: Five diverse H and N plans clinically delivered at our institution were selected. Isocenter for each plan was shifted positively and negatively in the three cardinal directions by a displacement equal to the PTV expansion on the CTV (3 mm) for a total of six shifted plans per original plan. The perturbed plan dose was recalculated in Eclipse (AAA v11.0.30) using the same, fixed fluence map as the original plan. The dose distributions for all plans were exported from the treatment planning system to determine the worst-case CTV dose distributions for each nominal plan. Two worst-case distributions, cold and hot, were defined by selecting the minimum or maximum dose per voxel from all the perturbed plans. The resulting dose volume histograms (DVH) were examined to evaluate the worst-case CTV and nominal PTV dose distributions. Results: Inspection demonstrates that the CTV DVH in the nominal dose distribution is indeed bounded by the CTV DVHs in the worst-case dose distributions. Furthermore, comparison of the D95% for the worst-case (cold) CTV and nominal PTV distributions by Pearson's chi-square test shows excellent agreement for all plans. Conclusion: The assumption that the nominal dose distribution for PTV represents the worst-case dose distribution for CTV appears valid for the five plans under examination. Although the worst-case dose distributions are unphysical since the dose per voxel is chosen independently, the cold worst-case distribution serves as a lower bound for the worst-case possible CTV coverage. Minor discrepancies between the nominal PTV dose distribution and worst-case CTV dose distribution are expected since the dose cloud is not strictly static. This research was supported by the NCI through grant K25CA168984, by The Lawrence W. and Marilyn W. Matteson Fund for Cancer Research, and by the Fraternal Order of Eagles Cancer Research Fund, the Career Development Award Program at Mayo Clinic.

60 APPLIED LIFE SCIENCES↗

TU-C-BRF-01: Innovation in Medical Physics and Engineering

We seek to heighten the awareness of the role of research and innovation that leads to clinical advances in the field of medical physics and engineering. Marie Curie (discovery and use of radium) and Harold Johns (Co-60 tele-therapy) in radiotherapy, and pioneers in imaging (Allan Cormack and Godfrey Hounsfield for the CT and Paul Lauterbur, Peter Mansfield for MRI, etc.) were scientists often struggling against great odds. Examples of more recent innovations that are clearly benefitting our patients include IMRT, Image Guided Radiation Therapy and Surgery, Particle Therapy, Quantitative imaging, amongst others.We would also like to highlight the fact that not all of the discovery and engineering that we benefit from in today’s world, was performed at research institutions alone. Rather, companies often tread new ground at financial and reputational risk. Indeed the strength of the private sector is needed in order to bring about new advances to our practice. The keys to long term success in research and development may very well include more public and private research spending. But, when more investigators are funded, we also need to recognize that there needs to be a willingness on the part of the funding institutions, academic centers and investigators to risk failure for the greater potential achievements in innovation and research. The speakers will provide examples and insight into the fields of innovation and research in medical physics from their own first hand experiences. Learning Objectives: To obtain an understanding of the importance of research and development towards advances in physics in medicine. To raise awareness of the role of interdisciplinary collaborations in translational research and innovation. To highlight the importance of entrepreneurships and industrial-institutional research partnerships in fostering new ideas and their commercial success. To recognize and account for the risk of failure for the greater potential achievements in innovation and research.

60 APPLIED LIFE SCIENCES↗

TU-E-BRD-01: President’s Symposium: The Necessity of Innovation in Medical Physics

This abstract will not blow you away, but speed-painting presenter Erik Wahl will certainly make a truly unique AAPM symposium that you will not want to miss. Along with clinical director John Bayouth and scientific leader Jeff Siewerdsen, this session will highlight innovation. To avoid being button pushers and irrelevant investigators of yesterday’s science, we must innovate. This is particularly challenging in the changing landscape of declining research funding and healthcare reimbursement. But all hope is not lost, Medical Physics is a field born out of innovation. As scientists we quickly translated the man-made and natural phenomena of radiation into a tool that could diagnose broken bones, locate foreign objects imbedded within the body, and treat a spectrum of diseases. As hyperbolae surrounding the curative powers of radiation overcame society, physicists continued their systematic pursuit of a fundamental understanding of radiation and applied their knowledge to enable the diagnostic and therapeutic power of this new tool. Health economics and the decline in research funding have put the Medical Physicist in a precarious position: how do we optimally participate in medical research and advanced patient care in the face of many competing needs? Today's diagnostic imaging and therapeutic approaches are tremendously sophisticated. Researchers and commercial vendors are producing technologies at a remarkable rate; to enable their safe and effective implementation Medical Physicists must work from a fundamental understanding of these technologies. This requires all of us, clinically practicing Medical Physicists, Researchers and Educators alike, to combine our training in scientific methods with innovation. Innovation is the key to our past, a necessity for our contemporary challenges, and critical for the future of Medical Physics. The keynote speakers for the 2014 AAPM Presidential Symposium session will address the way we approach these vitally important technologies for diagnosis and therapy into opportunities to innovate. The speed-painting artist and lecturer Erik Wahl will finish the symposium with a fast-paced and entertaining presentation on embracing the future by creating disruptive innovation strategies. Learning Objectives: Identify connection between Medical Physics and Innovation. Understand how Innovation enables Clinical Medical Physicists to implement novel technologies. Learn how innovative Medical Physics solutions can address significant and relevant challenges in science. Become inspired to pursue a new scientific understanding, positive change in clinical practice, and benefit to patients.

60 APPLIED LIFE SCIENCES↗

TU-F-18C-05: Evaluation of a Method to Calculate Patient-Oriented MGD Coefficients Using Estimates of Glandular Tissue Distribution

Purpose: Evaluate mammographic mean glandular dose (MGD) coefficients for particular known tissue distributions using a novel formalism that incorporates the effect of the heterogeneous glandular tissue distribution, by comparing them with MGD coefficients derived from the corresponding anthropomorphic computer breast phantom. Methods: MGD coefficients were obtained using MCNP5 simulations with the currently used homogeneous assumption and the heterogeneously-layered breast (HLB) geometry and compared against those from the computer phantom (ground truth). The tissue distribution for the HLB geometry was estimated using glandularity map image pairs corrected for the presence of non-glandular fibrous tissue. Heterogeneity of tissue distribution was quantified using the glandular tissue distribution index, Idist. The phantom had 5 cm compressed breast thickness (MLO and CC views) and 29% whole breast glandular percentage. Results: Differences as high as 116% were found between the MGD coefficients with the homogeneous breast core assumption and those from the corresponding ground truth. Higher differences were found for cases with more heterogeneous distribution of glandular tissue. The Idist for all cases was in the [−0.8{sup −}+0.3] range. The use of the methods presented in this work results in better agreement with ground truth with an improvement as high as 105 pp. The decrease in difference across all phantom cases was in the [9{sup −}105] pp range, dependent on the distribution of glandular tissue and was larger for the cases with the highest Idist values. Conclusion: Our results suggest that the use of corrected glandularity image pairs, as well as the HLB geometry, improves the estimates of MGD conversion coefficients by accounting for the distribution of glandular tissue within the breast. The accuracy of this approach with respect to ground truth is highly dependent on the particular glandular tissue distribution studied. Predrag Bakic discloses current funding from NIH, NSF, and DoD, former funding from Real Time Tomography, LLC and a current research collaboration with Barco and Hologic.

60 APPLIED LIFE SCIENCES↗